Lastly, we also found significantly reduced median OS for patients with IKZF1-mutated AML (7.5 months vs. 17.8 months, univariable HR: 1.74, p = 0.001, Table 2, Fig. 2C). This evidence concerns the gene IKZF1 and acute myeloid leukemia.